Unmasking Type – 1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 Inhibitor Use: A Case Report

Main Article Content

Simant Jha
Nitesh Kumar Singh
Anurag Mahajan


We describe here the case of a patient with Euglycemic DKA in the setting of SGLT-2 inhibitor use, further evaluation of which led to unmasking of Type-1 Diabetes Mellitus. There have been previous case reports where SGLT-2 inhibitor use has led to unmasking of diabetes mellitus type-1 in patients previously diagnosed with diabetes mellitus type-2.

We had a 57-year-old female with history of type 2 DM since last 10-12 years on Empagliflozin, Liraglutide, Metformin, Glimepiride and Pioglitazone presented with 5-hour history of shortness of breath which was acute in onset and was not associated with any other complaints. On initial evaluation, random blood sugar was 182 mg/dl. ABG showed high anion gap severe metabolic acidosis and Serum ketones levels were high. She was treated with IV fluids in the form of normal saline and was later switched to dextroseinfusion when her random blood sugar levels fell below 250 mg/dl, Insulin infusion and Potassium correction along with other supportive measures. her symptoms resolved with treatment over 3-4 days.

We did a literature review on the topic and present here the pathophysiology, Diagnosis, Management and Prevention of SGLT-2 inhibitor induced Euglycemic DKA.

Euglycemic Dka, sglt2 inhibitors, empagliflozin, euglycemic diabetic ketoacidosis.

Article Details

How to Cite
Jha, S., Singh, N. K., & Mahajan, A. (2020). Unmasking Type – 1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 Inhibitor Use: A Case Report. Asian Journal of Research and Reports in Endocrinology, 3(1), 1-5. Retrieved from https://journalajrre.com/index.php/AJRRE/article/view/30105
Case Study


Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Diabetes Res Clin Pract. 2017;130:53–60.

SGLT2 inhibitor-associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis. Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF. Clin Ther. 2016;38:2654–2664.

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. Ogawa W, Sakaguchi K. J Diabetes Investig. 2016;7: 135–138.

Sodium‐glucose co‐transporter 2 inhibitors and the risk for diabetic ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study. Kim YG, Jeon JY, Han SJ, Kim DJ, Lee K, Kim HJ. Diabetes Obes Metab. 2018;20: 1852–1858.

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. CurrOpin Endocrinol Diabetes Obes. 2017;24(1):73–79.

Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes technology & therapeutics. 2014;16(3):137–44.

Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: Evidence to date. Drug design, Development and Therapy. 2015;9:5793–803.

Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes ObesMetab. 2014;16(5): 457–66.

Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015;38(9):1638–42.

Bader N, Mirza L. Euglycemic diabetic ketoacidosis in a 27 year‐old female patient with type‐1‐diabetes treated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitor Canagliflozin. Pak J Med Sci. 2016;32(3):786‐788.

Kelmenson DA, Burr K, Azhar Y, Reynolds P, Baker CA, Rasouli N. Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium‐glucose cotransporter‐2 canagliflozin. J Investig Med High Impact Case Rep. 2017;5(2):2324709617712736.

Cefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183-7.

Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes care. 2015; 38(7):1218–27.

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: A meta-analysis. Cardiovasc Diabetol. 2016; 15(1):37.

Gajjar K, Luthra P. Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature. Cureus. 2019;11(4):e4384.
[Published 2019 Apr 4]